Abstract： Objective： To investigate the potential active components， key targets， and mechanism of Yule Granulesin treating depression，thusproviding a scientific basisforclinicalapplication.Methods：Network pharmacology methods were employed to identify depression-related targets from GeneCards， OMIM， and TTD databases， which were then cross-referenced with Yule Granules'active component targets. A "drug-active component-disease-target" network and protein-protein interaction（PPI）network were constructed using Cytoscape，with core active components and key targets analyzed via CytoNCA. STRING database facilitated PPI network topology analysis，while GO functional enrichment and KEGG pathway analyses elucidated potential pathways. Molecular docking validated binding activities between active components and core targets. Results： A total of 851 potential targets of Yule Granules in treating depression were identified. Core active components included naringenin， coumaroyltyramine， 1，4-epoxy-16- hydroxyeneicos-1，3，12，14，18-pentaene，and kaempferol，with key targets such as GAPDH，AKT1，TP53，and TNF. GO analysis revealed involvement in protein phosphorylation and inflammatory responses，while KEGG analysis indicated actions through neuroactive ligand-receptor interaction， MAPK， cAMP， and neurotrophin signaling pathways. Molecular docking demonstrated relatively low binding energy（-5.4 to -10.3 kcal/mol），with strong binding affinity between core components and targets. Conclusion：Yule Granules likely exerts antidepressant effects through multi-component，multi-target，and multi-pathway synergistic actions，involving neurotransmitter regulation，antiinflammatory responses，neuroprotection，and cellular metabolism modulation，embodying the holistic and synergistic therapeutic principles of traditional Chinese medicine.